Royal Sense Ltd
Incorporated in 2023, Royal Sense Ltd is in the business of trading of pharmaceutical products[1]
- Market Cap ₹ 93.6 Cr.
- Current Price ₹ 175
- High / Low ₹ 310 / 122
- Stock P/E 30.5
- Book Value ₹ 56.3
- Dividend Yield 0.00 %
- ROCE 18.0 %
- ROE 14.2 %
- Face Value ₹ 10.0
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Sep 2023 6m | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|
| 8.03 | 18.96 | 27.64 | 37.33 | |
| 7.09 | 16.59 | 23.39 | 32.79 | |
| Operating Profit | 0.94 | 2.37 | 4.25 | 4.54 |
| OPM % | 11.71% | 12.50% | 15.38% | 12.16% |
| 0.01 | 0.03 | 0.08 | 0.08 | |
| Interest | 0.00 | 0.09 | 0.18 | 0.50 |
| Depreciation | 0.00 | 0.01 | 0.02 | 0.03 |
| Profit before tax | 0.95 | 2.30 | 4.13 | 4.09 |
| Tax % | 26.32% | 26.09% | 26.15% | |
| 0.70 | 1.70 | 3.04 | 3.07 | |
| EPS in Rs | 2.03 | 3.47 | 6.12 | 5.89 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 70% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 5% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -27% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 14% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|
| Equity Capital | 4.90 | 4.97 | 5.35 |
| Reserves | 13.44 | 19.60 | 24.77 |
| 1.60 | 3.26 | 6.79 | |
| 0.94 | 3.02 | 6.76 | |
| Total Liabilities | 20.88 | 30.85 | 43.67 |
| 0.05 | 1.65 | 1.73 | |
| CWIP | 0.00 | 0.00 | 0.00 |
| Investments | 0.43 | 0.44 | 0.44 |
| 20.40 | 28.76 | 41.50 | |
| Total Assets | 20.88 | 30.85 | 43.67 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Sep 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| -0.79 | 1.80 | ||
| -4.55 | -11.07 | ||
| 13.10 | 2.89 | ||
| Net Cash Flow | 7.77 | -6.39 | |
| Free Cash Flow | -0.82 | 0.18 | |
| CFO/OP | -33% | 58% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Sep 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| Debtor Days | 90.48 | 117.79 | |
| Inventory Days | 6.27 | 53.66 | |
| Days Payable | 0.46 | 22.43 | |
| Cash Conversion Cycle | 96.29 | 149.02 | |
| Working Capital Days | 118.78 | 100.63 | |
| ROCE % | 18.04% |
Insights
In beta| Mar 2024 | Mar 2025 | |
|---|---|---|
| Geographic Presence (Number of States/Regions) Number |
|
|
| Net Capital Turnover Ratio Ratio |
||
| Number of Permanent Employees Number |
||
| US FDA Approved Products Number |
||
| E-Commerce Distribution Partnerships (Zepto/Blinkit) Number |
||
| Number of New Products Launched (Annual) Number |
||
Documents
Announcements
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
2d - Regulation 74(5) compliance certificate for quarter ended 31 March 2026; all shares in demat form.
-
Reply To The Clarification Sought On Movement In Price Of The Shares Across Exchange Of Shares.
8 Apr - Royal Sense says recent share price movement is market-driven; all material disclosures are already public.
-
Clarification sought from Royal Sense Ltd
7 Apr - Exchange has sought clarification from Royal Sense Ltd on April 7, 2026 with reference to significant movement in price, in order to ensure that investors …
- Closure of Trading Window 23 Mar
-
Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer
28 Feb - Ms. Ragini Maurya resigned as Company Secretary & Compliance Officer effective 28-Feb-2026.
Business Overview:[1][2]
a) In FY23, Royal Traders, PHT, and Anaya merged to form a unified entity under the name Royal Sense Limited (RSL).
b) RSL supplies goods that meet international standards for hospitals, laboratories, institutions, and clinics. It offers a wide range of surgical accessories, tools, and equipment, which can be customized as per client requirements.
c) RSL specializes in medical device manufacturing as well as pharmaceuticals trading.
d) The company provides a comprehensive portfolio of products and services—from medical devices to essential drugs—catering to the diverse needs of healthcare providers and patients.